+91-8668442535

Cancer Biomarkers Market By Type (Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers), By Type of Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer), By Type of Profiling Technologies (Immunoassays, Omics Technologies, Cytogenetics, Imaging Technologies, Bioinformatics), By Application (Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment) - Growth, Future Prospects, and Competitive Analysis, 2017-2025

The report titled "Cancer Biomarkers Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall cancer biomarkers market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of cancer, type of profiling technologies, type of application, and different geographies. Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of the progression of the disease. Factors such as the rising prevalence of cancer, increasing support from government and non-government organizations for cancer biomarker research, an aging population, and the increasing use of biomarkers in the drug discovery and development process

For the purpose of this study, the global cancer biomarker market is segmented on the basis of type into genetic biomarkers, epigenetic biomarkers, metabolic biomarkers, proteomic biomarkers, and others. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

On the basis of types of cancer, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, etc. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global cancer biomarker market is also segmented on the basis of the type of profiling technologies used, such as immunoassays, omics technologies, cytogenetics, imaging technologies, and bioinformatics. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global cancer biomarker market is segmented on the basis of the type of application, such as diagnostics, drug discovery and development, prognostics, risk assessment, and others. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the cancer biomarkers market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The cancer biomarkers market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Affymetrix, Inc., DiagnoCure, Inc., Qiagen NV, Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies, Inc., Merck & Co., Inc., Hologic, Inc., and Becton Dickinson and Company, among others.

Based on type, the global cancer biomarkers market is segmented as follows:

  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Other Biomarkers

In 2016, proteomic biomarkers dominated the market by type due to the exceptional market potential of protein biomarkers in diagnostics, prognostics, cancer detection, and other clinical and therapeutic applications. In addition, the increasing focus of pharmaceutical and biotechnology companies on research and development of protein biomarkers is expected to fuel overall market growth. During the forecast period of 2017–2025, epigenetics was observed as the fastest-growing segment as it gained high acceptance in the cancer diagnostics industry. The key factors driving the growth of the epigenetics segment are the high amount of research carried out by many players for the analysis of key epigenetic modifications and the increasing collaboration between diagnostic and pharmaceutical companies for developing precise diagnoses and target-specific treatments.

Based on the type of profiling technologies, the global cancer biomarkers market is segmented as follows:

  • Immunoassays
  • Omics Technologies
  • Cytogenetics
  • Imaging Technologies
  • Bioinformatics

Because of key driving factors such as increased adoption of advanced high-throughput technologies in biomarker discovery and development and the rising application of omics-based tests for cancer diagnosis and the drug development process, omics technologies accounted for the largest share of the cancer biomarkers market in 2016 and were also the fastest-growing segment. In addition, incessant developments in high-throughput omics technologies are also backing the growth of this market by expanding the space for prospective biomarkers in cancer research.

Based on the type of cancer, the global cancer biomarkers market is segmented as follows:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Others

In 2016, breast cancer dominated the cancer biomarkers market by cancer type due to the rising prevalence of the disease, high awareness associated with early diagnosis, increasing public awareness with the assistance of government and non-government organizations, and rising research and development activities in the field of a breast cancer diagnosis. During the forecast period of 2017–2025, lung cancer was observed as the fastest-growing segment due to key driving factors such as the rising prevalence of lung cancer due to an increase in air pollution and frequent smoking observed in the younger generation.

Based on the type of application, the global cancer biomarkers market is segmented as follows:

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others

The rising prevalence of cancer, increasing demand for efficient diagnosis techniques against cancer, developing research activities in the field of cancer biomarkers, and increasing awareness associated with an early cancer diagnosis are the key factors driving the overall cancer biomarkers market. In 2016, the applications segment was dominated by diagnostics due to key driving factors such as increasing public awareness about the importance of early diagnosis of cancer and the fact that diagnostic biomarkers enable doctors to decide effective treatment alternatives.

For the purpose of this study, the global cancer biomarkers market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2016, North America accounted for the largest share in the global cancer biomarkers market due to key driving factors such as the high prevalence of cancer, mounting healthcare expenditure leading to a rise in demand for efficient diagnostic tests and healthcare services, and incessant technological advancements in the cancer biomarkers industry. According to the American Cancer Society, in 2017, about 190,500 cancer deaths in the US were caused by cigarette smoking alone.

An estimated 20% of all cancers diagnosed in the US are caused by a combination of excess body weight, physical inactivity, excess alcohol consumption, and poor nutrition, and thus could also be prevented. During the forecast period of 2017–2025, Asia Pacific was observed as the fastest-growing region in the cancer biomarkers market due to the rising prevalence and awareness of cancer, supportive government policies, market expansion by key market players, and rising application of biomarker tests for cancer diagnosis.

Frequently Asked Questions:

The market for Cancer Biomarkers Market is expected to reach USD 30,284.5 Mn By 2025.

The Cancer Biomarkers Market is expected to see significant CAGR growth over the coming years, at 11.5%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Affymetrix, Inc., DiagnoCure, Inc., Qiagen NV, Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies, Inc., Merck & Co., Inc., Hologic, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58676
Report Format:   PDF
Pages:   120
Rating:    4.5 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support